^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    KIT exon 17 mutation

    i
    Other names: KIT, C-Kit, CD117, PBT, SCFR, Stem Cell Factor Receptor, V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog
    Entrez ID:
    3815
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    Apply
    Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. (NCT06087263)
    Phase 2
    M.D. Anderson Cancer Center
    Not yet recruiting
    Last update posted :
    04/23/2024
    Initiation :
    04/30/2024
    Primary completion :
    07/01/2032
    Completion :
    07/01/2034
    SDHB
    |
    KIT exon 17 mutation • SDHB mutation • KIT exon 17 mutation + KIT exon 18 mutation
    |
    imatinib • Stivarga (regorafenib)
    Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies (AZURE) (NCT05609942)
    Phase 1/2
    Blueprint Medicines Corporation
    Recruiting
    Last update posted :
    04/02/2024
    Initiation :
    09/25/2023
    Primary completion :
    11/30/2029
    Completion :
    11/30/2029
    PDGFRA
    |
    KIT mutation • PDGFRA D842V • PDGFRA mutation • KIT D816V • KIT exon 17 mutation • PDGFRA fusion
    |
    azacitidine • elenestinib (BLU-263)
    ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST (NCT05366816)
    Phase 2
    University of Miami
    Recruiting
    Last update posted :
    10/23/2023
    Initiation :
    10/17/2023
    Primary completion :
    12/01/2026
    Completion :
    12/01/2028
    KIT
    |
    KIT exon 13 mutation • KIT exon 17 mutation
    |
    sunitinib • Stivarga (regorafenib)
    cKIT, BRAF/NRAS Mutations in Advanced Melanoma : Clinical Outcome in Response to Tyrosine-kinase Inhibitors - KitMel Project (NCT01543113)
    Phase N/A
    Rennes University Hospital
    Completed
    Last update posted :
    05/24/2023
    Initiation :
    01/01/2011
    Primary completion :
    03/01/2012
    Completion :
    02/01/2014
    KIT • RAS
    |
    NRAS mutation • RAS mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation
    Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST (REGISTRI) (NCT02638766)
    Phase 2
    Grupo Espanol de Investigacion en Sarcomas
    Completed
    Last update posted :
    03/27/2023
    Initiation :
    11/01/2015
    Primary completion :
    08/31/2021
    Completion :
    08/31/2021
    KIT
    |
    KIT mutation • KIT exon 11 mutation • KIT exon 13 mutation • KIT exon 17 mutation • KIT wild-type • PDGFR wild-type
    |
    Stivarga (regorafenib)
    PDR001 Plus Imatinib for Metastatic or Unresectable GIST (NCT03609424)
    Phase 1/2
    Asan Medical Center
    Completed
    Last update posted :
    01/02/2023
    Initiation :
    02/14/2019
    Primary completion :
    11/11/2021
    Completion :
    11/11/2021
    KIT • CD8 • PD-1 • LAG3 • ANO1 • MSR1
    |
    KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT exon 13 mutation • KIT exon 17 mutation
    |
    imatinib • sunitinib • Stivarga (regorafenib) • spartalizumab (PDR001)
    Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors (ZJGIST-01) (NCT04933669)
    Phase 2
    First Affiliated Hospital of Zhejiang University
    Recruiting
    Last update posted :
    10/12/2021
    Initiation :
    09/07/2021
    Primary completion :
    12/31/2029
    Completion :
    12/31/2029
    KIT • PDGFRA • ANO1
    |
    KIT mutation • KIT exon 11 mutation • KIT exon 9 mutation • KIT positive • PDGFRA mutation • KIT exon 13 mutation • KIT exon 17 mutation
    |
    imatinib
    Regorafenib in GIST With Secondary C-KIT Exon 17 Mutation (NCT02606097)
    Phase 2
    Chang Gung Memorial Hospital
    Completed
    Last update posted :
    03/21/2019
    Initiation :
    04/01/2014
    Primary completion :
    05/01/2018
    Completion :
    05/01/2018
    KIT
    |
    KIT mutation • KIT exon 17 mutation
    |
    Stivarga (regorafenib)